ZBIO - Total Utang marang Modal Zenas Corp
Zenas Biopharma Inc (ZBIO) ensures the seamless delivery of biomaterials for testing via reliable couriers and implements ESG standards in the production of immune agents. This debt-to-equity chart visualizes financial stability, where 1.58 defines the current value of the metric. Zenas Biopharma Inc (ZBIO) leverages global research alliances and joint clinical programs to develop innovative treatment methods.
%20-%20Rasio%20Kabeh%20Utang%20marang%20Dana%20Pribadi&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_ZBIO_-_Zenas-Biopharma-Inc_-_All-Debt-to-Shareholders-Equity-Ratio "ZBIO (Zenas Biopharma Inc) riwayat Total Utang marang Modal saka 14.09.2024 nganti 31.10.2026 | 👁️GURU.Markets👁️")
Rincian analitis perusahaan Zenas Biopharma Inc
- rega lan prakiraan konsensus rega:
- statistik kapitalisasi pasar:
- indikator kapitalisasi buku:
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Zenas Biopharma Inc|ZBIO - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Zenas Biopharma Inc|ZBIO - Gunggung utang perusahaan|Utang marang nilai buku Zenas Biopharma|ZBIO - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Zenas Biopharma|Likuiditas cepet zenasbio.com
- informasi bathi lan kelipatan valuasi:
Analisis dhasar perusahaan:Zenas Biopharma
Zenas Biopharma Inc (ZBIO) is of interest to investors as a high-tech player in the immunotherapy sector. This ratio compares total liabilities to net assets to determine the level of financial leverage. By analyzing changes in the debt-to-equity ratio, one can assess over-leverage risks during the implementation of an expansion strategy. For a biotech startup, the balance between debt and equity is critical when funding clinical phases. The stability of this ratio confirms the resilience of the development model.
Analisis pesaing Zenas Biopharma Inc
Utang marang Ekuitas argenx|BioNTech Inc. - Utang Agregat marang Ekuitas|Total Utang marang Modal ABVX|ADMA (ADMA Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal PTGX (Protagonist Therapeutics)|Total Utang marang Modal immunovant.com IMVT|KNSA - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi GRFS (Grifols SA)|Adaptive Biotechnologies Corp (ADPT) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Celldex Corp|AUPH (Aurinia Pharmaceuticals) - Total Utang marang Modal|Total Utang marang Modal biocryst.com|Rasio Total Utang marang Ekuitas VERA (Vera Therapeutics)|DNTH (Dianthus Therapeutics Inc) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal PHVS (Pharvaris Corp)|Koefisien Total Utang marang Modal AbCellera (ABCL)|TRML - Utang marang Ekuitas|precigen.com (PGEN) - Rasio Total Utang marang Ekuitas|Pharming Group (PHAR) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Nektar Therapeutics Inc|Rasio Total Utang marang Ekuitas UPB|Total Utang marang Modal Immunome Bio|Utang marang Ekuitas Gossamer Bio, Inc. (GOSS)|kalvista.com - Rasio Utang marang Ekuitas|Total Utang marang Modal SEPN (Septerna)|Pieris Pharma (PVLA) - Utang marang Modal|SVRA: Rasio Total Utang marang Ekuitas|Utang Agregat marang Ekuitas RIGL|ANAB: Total Utang marang Modal|Utang marang Modal astriatx.com (ATXS)|Utang marang Ekuitas enGene|Rasio Utang marang Ekuitas RAPT (RAPT Therapeutics Inc.)|Total Utang marang Modal JBIO|Total Utang marang Modal Aclaris Therapeutics, Inc (ACRS)|Utang marang Ekuitas Kyverna Therapeutics KYTX|Koefisien Total Utang marang Modal tizianalifesciences.com (TLSA)|CABA: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi VTYX (Ventyx Biosciences Inc.)|THTX: Total Utang marang Modal|AVTX (Avalo Therapeutics Inc) - Utang marang Ekuitas|ELDN (Eledon Pharmaceuticals) - Total Utang marang Modal|agenusbio.com (AGEN) - Koefisien Total Utang marang Modal|Utang marang Ekuitas Climb Bio (CLYM)|ZURA - Utang marang Modal|Utang marang Ekuitas aTyr ATYR|ADAG (Adagene Inc) - Utang Agregat marang Ekuitas|Ikena Oncology, Inc. - Total Utang marang Modal|Rasio Kabeh Utang marang Dana Pribadi STTK (Shattuck Labs, Inc.)|EQ: Total Utang marang Modal|Connect Biopharma Holdings Limited (CNTB) - Total Utang marang Modal|Utang marang Ekuitas Immunic Therapeutics|ATRA: Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas InflaRx N.V. (IFRX)|Rasio Total Utang marang Ekuitas x4pharma.com XFOR|Total Utang marang Modal ACET (Adicet Bio, Inc.)|Total Utang marang Modal Celularity Inc CELU|INMB: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi BRNS (Barinthus Biotherapeutics Corp)|KZR: Total Utang marang Modal|SABS - Koefisien Total Utang marang Modal|Utang marang Ekuitas Akari Therapeutics Plc|Rasio Utang marang Ekuitas ENLV (Enlivex Therapeutics, Ltd.)|Total Utang marang Modal QTTB|Rasio Total Utang marang Ekuitas GeoVax Corp GOVX|Edesa Biotech, Inc. - Rasio Total Utang marang Ekuitas|IBIO (ibioinc.com) - Utang Agregat marang Ekuitas|Carisma Tx - Total Utang marang Modal|XTLB: Utang marang Ekuitas|BOLT: Total Utang marang Modal|HCWB - Koefisien Total Utang marang Modal|Utang marang Ekuitas Aptevo Therapeutics, Inc.|Utang marang Modal AIM ImmunoTech, Inc. AIM|Utang marang Ekuitas Aditxt (ADTX)|GRI: Utang Agregat marang Ekuitas|Total Utang marang Modal XRTX (XORTX)|Rasio Kabeh Utang marang Dana Pribadi HIND|Revelation Biosciences - Total Utang marang Modal|INDP - Total Utang marang Modal|Scinai Immunotherapeutics Ltd. (SCNI) - Utang marang Ekuitas|CalciMedica - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Affimed NV|Rasio Total Utang marang Ekuitas Allakos Therapeutics (ALLK)|Total Utang marang Modal HOOK|Total Utang marang Modal igmbio.com (IGMS)|iTeos Therapeutics, Inc. - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi OCEA|TC BioPharm (Holdings) PLC - Total Utang marang Modal|Koefisien Total Utang marang Modal Third Harmonic Bio Inc THRD